Honest Criticisms and Limitations of the ODYSSEY OUTCOMES Trial
A deep-dive into the enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest concerns surrounding the ODYSSEY OUTCOMES trial of alirocumab post-ACS.
Trials Odyssey Outcomes
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Odyssey Outcomes library
Showing 8 of 8 clinical reviews.
Inside the ODYSSEY OUTCOMES Methodology: What Most Summaries Skip
A detailed breakdown of the ODYSSEY OUTCOMES trial design, randomization, blinding, endpoint adjudication, and statistical framework that produced the 15% MACE reduction for alirocumab after acute coronary syndrome.
ODYSSEY OUTCOMES Cost, Cost-Effectiveness, and Health-Economic Implications
Deep-dive into cost-effectiveness analyses from the ODYSSEY OUTCOMES trial of alirocumab, including cost per QALY, payer coverage shifts, list-price vs net-price dynamics, and patient-level value calculations.
ODYSSEY OUTCOMES Extension Data and What Happened After the Trial Ended
Deep-dive into long-term follow-up from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, covering durability of MACE reduction, safety signals beyond the primary analysis, and what clinicians should know about sustained PCSK9 inhibition.
ODYSSEY OUTCOMES Results in Detail: Numbers, Subgroups, and Time Course
A deep-dive into the ODYSSEY OUTCOMES trial results for alirocumab post-ACS, covering primary and secondary endpoints, effect sizes, confidence intervals, time-course patterns, and subgroup analyses.
ODYSSEY OUTCOMES Subgroup Analyses: Who Responded Most and Least
Deep-dive into pre-specified and post-hoc subgroup analyses from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, examining differential MACE reduction by age, sex, BMI, baseline LDL-C, diabetes status, and more.
ODYSSEY OUTCOMES Trial: A Plain-English Overview of What It Established
A deep-dive overview of the ODYSSEY OUTCOMES trial, explaining how alirocumab reduced major cardiovascular events in patients after acute coronary syndrome already on high-intensity statins.
What ODYSSEY OUTCOMES Actually Changes in Clinical Practice
A deep-dive into the ODYSSEY OUTCOMES trial examining how alirocumab's 15% MACE reduction in post-ACS patients on high-intensity statins reshaped guidelines, prescribing patterns, and real-world cardiology decision-making.